Frost & Sullivan Research Service   Published: 1 Jul 2002
U.S. Lipid Regulators Markets
  SERVICE HOMEPAGE
REPORT OVERVIEW BENEFITS OF THIS SERVICE MARKET SECTORS
TECHNOLOGIES LIST OF FIGURES ANALYST PRESENTATION
TABLE OF CONTENTS ORDERING INFORMATION FURTHER INFORMATION
   Report Overview
  Low Awareness Limits Market Potential

While drugs that can lower cholesterol and reduce the risk of cardiovascular disease by reducing lipid levels have been on the market for over three decades, a sizable portion of the dyslipidemic population remains untreated. Thus, major pharmaceutical companies need to aggressively pursue physician awareness initiatives and direct-to-consumer campaigns to bridge the gap.

This Frost & Sullivan study analyzes the U.S. markets for lipid regulators, including a full range of statin and non-statin products. It tracks changes in demand and the development of new products. With its discussion of key industry challenges and presentation of expert revenue forecasts, this study offers your firm an essential guide to the future of the field.

Generics, New Combination Therapies Threaten Established Products

"The loss of patent exclusivity for lipid reducers will lead to the introduction of low-cost generics," says the studys author. "Although generics will benefit patients, they will also constrain market revenues for branded products." Competition will intensify in statin markets in the medium term, when the patents for two major brands expire.

At the same time, newer, more potent lipid-lowering agents could usurp market share from incumbent brands. "The development of combination lipid-lowering agents could cannibalize the market and pose a challenge to sustaining growth trends," states the analyst. By evaluating the threat from generics and assessing the impact of new products on the marketplace, this study will enable your company to target the most lucrative areas.

New Clinical Trials Should Spark Interest in Lipid Regulators

"A number of large clinical trials have recently demonstrated the benefits associated with improving the lipid profile," says the author. These studies have established the role of statins in correcting dyslipidemia and reversing coronary heart disease. "Because most physicians base prescription decisions on the results of large clinical trials, doctors who are aware of statins are gaining confidence in their use."

Meanwhile, the publication of guidelines by influential healthcare organizations that advocate aggressive management of dyslipidemia should inspire more doctors to investigate and prescribe lipid-reducing products. This study, which identifies market drivers and restraints, will help your firm prepare for the challenges and opportunities that lie ahead.

   Benefits of this Service
 

Benefits of Using Frost & Sullivan Market Engineering and Other Research Services

Market-Driven vs. Technology-Driven

Close monitoring of market positions with customers and competitors allows product teams to become market-oriented.

Proactive vs. Reactive

Monitoring markets more frequently and with expanded measurements enables a company to lead the market rather than follow it.

Investment with Return vs. Budget Expense

Because Frost & Sullivan focuses on solution-based consulting, a companys investment in our consulting will return higher sales and profits.

Solid Reputation vs. Biased Internal Source

Frost & Sullivan enjoys a reputation as a world leader in market consulting, having gained the respect of the world financial and industrial community for unbiased reporting and analysis of market situations.

Market Efficiency vs. Strategy Based on Last Year

Our up-to-the-minute, measurement-based marketing system drives the improvement of marketing efficiency through constant comparison of cost versus benefit on every product, marketing campaign, project, department, and service.

Cost Effectiveness vs. Internal Budget Waste

Using Frost & Sullivan as a strategic partner gives a client cost savings advantages: reduced start-up time, access to huge industry databases, and reduced staff and overhead.

Critical Applications

  • Strategy Development
  • Product Introduction
  • Competitive Threat
  • Acquisition Analysis
  • R&D Investment Analysis
  • New Idea Search
  • Poor Sales Performance
  • Distribution Strategy
  • New Technology

   Market Sectors
  Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this Service:
  • By product type: Statin products and Non-statin Products

   Technologies
 
  • Statins: Statins are the new "wonder drugs" that lower LDL and control increasing HDL cholesterol levels. All statins fall under the same class of drugs (3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase inhibitors). However, each statin is unique either due to some distinct benefit or skewed clinical trial results. Statins not only slow the progression, but aid the regression of atherosclerosis. In this report statin products include branded, generic, and combination statins.
  • Non-Stanins: Non- Stanins or Fibric-acid derivatives (fibrates) have primarily been used for lowering triglycerides (TG) due to its moderate effect on the other lipids. Prior to the introduction of statins, fibrates were used as first-line therapy for cholesterol management, including treatment of LDL cholesterol because of lack of alternatives. Presently, the use of fibrates is restricted to hypertriglyceridemia and mixed dyslipidemia patients. Due to established efficacy of fibrates in reducing triglycerides, physicians prescribe fibrates along with a statin in the patients suffering from mixed dyslipidemia. The non-statin products market includes fibric-acid derivatives, bile-acid sequestrants, nicotinic-acid derivatives, and new products in development.

   Analyst Presentation
  Click here to view the analyst presentation:
 

  Table Of Contents
  1 | EXECUTIVE SUMMARY
   Executive Summary
      1. Executive Summary

  2 | TOTAL MARKET
   Overview
      1. Introduction
      2. NCEP Guidelines
      3. Analysis

  Forecasts and Trends
      1. Demand Analysis
      2. Revenue Forecasts
      3. Pricing Analysis
      4. Technology Trends

  Challenges and Strategies
      1. Strategies Overview
      2. Low Awareness Limits Drug Utilization to High-Risk Patients
      3. Non-Adherence to NCEP Guidelines by Physicians Truncates Growth
      4. Poor Compliance Decimates Growth Potential
      5. Introduction of Low Cost Generics to Constrain Market Expansion
      6. Introduction of Combination Drugs Threatens Sustenance of Growth Trends

  Awards
      1. Marketing Strategy Leadership Award - Pfizer
      2. Business Development Strategy Award - Merck and Co.
      3. Competitive Strategy Award - Bristol-Myers Squibb
      4. Product Launch Strategy Award - KOS Pharmaceuticals
      5. Technology Innovation Award - Avant Immunotherapeutics

  3 | STATINS MARKET
   Branded Statins Market Overview
      1. Introduction
      2. Analysis
      3. Market Drivers
      4. Market Restraints
      5. Demand Analysis
      6. Revenue Forecasts
      7. Pricing Analysis
      8. Competitive Structure
      9. Product Analysis
      10. Market Share Analysis

  Statin Combinations Market Overview
      1. Introduction
      2. Analysis
      3. Market Drivers
      4. Market Restraints
      5. Demand Analysis
      6. Revenue Forecasts
      7. Product Analysis

  Generic Statin Market Overview
      1. Impact of Generics
      2. Demand Analysis
      3. Revenue Forecasts

  4 | NON-STATINS MARKET
   Fibric-Acid Derivatives Market
      1. Overview
      2. Analysis
      3. Demand Analysis
      4. Revenue Forecasts
      5. Product Analysis

  Bile-Acid Sequestrants Market
      1. Overview
      2. Analysis
      3. Revenue Forecasts

  Nicotinic Acid Derivatives Market
      1. Overview
      2. Analysis
      3. Revenue Forecasts

  New Products Market
      1. Overview
      2. Revenue Forecasts
      3. Product Analysis

  5 | DECISION SUPPORT DATABASE
   Causal Factors
      1. Incidence of Myocardial Infarction
      2. Mortality due to Myocardial Infarction
      3. Mortality due to Coronary Heart Disease
      4. Prevalence percent of Cardiovascular Diseases
      5. Prevalence of Obese Population
      6. Diabetes Prevalence
      7. Prevalence of Hypertension

  Demographics
      1. Male Population over 65 Years of Age
      2. Female Population over 65 Years of Age
      3. Total Population over 65 Years of Age

   List of Figures
  Chapter 2
  • Lipid Regulators Markets: Database of Key Industry Participants by Product Type (U.S.), 2001
  • Lipid Regulators Markets: Demand Analysis (U.S.), 1998-2008
  • Lipid Regulators Markets: Percent of Patients by Product Type
    U.S.), 1998-2008
  • Lipid Regulators Markets: Revenue Forecasts (U.S.), 1998-2008
  • Lipid Regulators Markets: Percent of Revenues by Product Type
  • (U.S.), 1998-2008
  • Lipid Regulators Markets: Market Share Trends of Major Market Participants (U.S.), 2000-2001
  • Lipid Regulators Markets: Major Events Influencing Market Revenues (U.S.), 2001-2008
  • Lipid Regulators Markets: Annual Cost of Therapy Trends (U.S.), 1998-2008
  • Lipid Regulators Markets: Pricing Analysis (U.S.), 1999-2001
  • Lipid Regulators Markets: Products in Development (U.S.), 2001-2002
  • Lipid Regulators Markets: Anticipated Product Introductions (U.S.), 2003-2009
  • Lipid Regulators Markets: Impact of Top Five Industry Challenges (U.S.), 2002-2008
  • Lipid Regulators Markets: Strategies Addressing Top Five Market Challenges (U.S.), 2002

Chapter 3
  • Total Statins Market: Revenue Forecasts (U.S.), 1998-2008
  • Total Statins Market: Percent of Revenues by Product Type (U.S.), 1998-2008
  • Total Statins Market: Demand Analysis (U.S.), 1998-2008
  • Total Statins Market: Percent of Patients by Product Type (U.S.), 1998-2008
  • Branded Statins Market: Market Drivers Ranked in Order of Impact (U.S.), 2002-2008
  • Branded Statins Market: Market Restraints Ranked in Order of Impact (U.S.), 2002-2008
  • Branded Statins Market: Demand Analysis (U.S.), 1998-2008
  • Branded Statins Market: Patients by Product (U.S.), 1998-2008
  • Branded Statins Market: Percent of Patients by Product (U.S.), 1998-2008
  • Branded Statins Market: Revenue Forecasts (U.S.), 1998-2008
  • Branded Statins Market: Revenue Forecasts by Product (U.S.), 1998-2008
  • Branded Statins Market: Percent of Revenues by Product (U.S.), 1998-2008
  • Branded Statins Market: Product Efficacy at Starting Doses (U.S.), 2001
  • Branded Statins Market: Competitive Structure (U.S.), 2001
  • Branded Statins Market: Product Efficacy (U.S.), 2001
  • Branded Statins Market: Product Efficacy at Starting Doses (U.S.), 2001
  • Branded Statins Market: Product Analysis - Mevacor (U.S.), 2001
  • Branded Statins Market: Product Analysis - Zocor (U.S.), 2001
  • Branded Statins Market: Product Analysis - Pravachol (U.S.), 2001
  • Branded Statins Market: Product Analysis - Lescol (U.S.), 2001
  • Branded Statins Market: Product Analysis - Lipitor (U.S.), 2001
  • Branded Statins Market: Product Analysis (U.S.), 2001
  • Branded Statins Market: Market Share Analysis (U.S.), 1998-2008
  • Statin Combinations Market: Market Drivers Ranked in Order of Impact (U.S.), 2002-2008
  • Statin Combinations Market: Market Restraints Ranked in Order of Impact (U.S.), 2002-2008
  • Statin Combinations Market: Demand Analysis (U.S.), 1998-2008
  • Statin Combinations Market: Patient Forecasts by Product (U.S.), 1998-2008
  • Statin Combinations Market: Percent of Patients by Product (U.S.), 1998-2008
  • Statin Combinations Market: Revenue Forecasts (U.S.), 1998-2008
  • Statin Combinations Market: Revenue Forecasts by Product (U.S.), 1998-2008
  • Statin Combinations Market: Percent of Revenues by Product
    (U.S.), 1998-2008
  • Statin Combinations Market: Product Analysis - Advicor (U.S.), 2002
  • Generic Statins Market: Demand Analysis (U.S.), 1998-2008
  • Generic Statins Market: Statin Monotherapy Patient Forecasts
    (U.S.), 1998-2008
  • Generic Statins Market: Patient Forecasts by Product (U.S.), 1998-2008
  • Generic Statins Market: Percent of Patients by Product (U.S.), 1998-2008
  • Generic Statins Market: Revenue Forecasts (U.S.), 1998-2008
  • Generic Statins Market: Statin Monotherapy Revenue Forecasts
    (U.S.), 1998-2008
  • Generic Statins Market: Revenues by Product (U.S.), 1998-2008
  • Generic Statins Market: Percent of Revenues by Product (U.S.), 1998-2008

Chapter 4
  • Non-Statin Products Market: Products Offered by Major Market Participants (U.S.), 2001
  • Non-Statins Market: Demand Analysis (U.S.), 1998-2008
  • Non-Statins Market: Percent of Patients by Product Type (U.S.), 1998-2008
  • Non-Statins Market: Revenue Forecasts (U.S.), 1998-2008
  • Non-Statins Market: Percent of Revenues by Product Type (U.S.), 1998-2008
  • Fibric-Acid Derivatives Market: Demand Analysis (U.S.), 1998-2008
  • Fibric-Acid Derivatives Market: Percent of Patients by Product (U.S.),
    1998-2008
  • Fibric-Acid Derivatives Market: Revenue Forecasts (U.S.), 1998-2008
  • Fibric-Acid Derivatives Market: Percent of Revenues by Product (U.S.),
    1998-2008
  • Fibric-Acid Derivatives Market: Product Efficacy (U.S.), 2001
  • Bile-Acid Sequesterants Market: Demand Analysis (U.S.), 1998-2008
  • Bile-Acid Sequesterants Market: Revenue Forecasts (U.S.), 1998-2008
  • Nicotinic-Acid Derivatives Market: Demand Analysis (U.S.), 1998-2008
  • Nicotinic-Acid Derivatives Market: Revenue Forecasts (U.S.), 1998-2008
  • New Non-Statin Products Market: Products in Advanced Stage of Development (U.S.), 2001
  • New Non-Statin Products Market: Demand Analysis (U.S.), 1998-2008
  • New Non-Statin Products Market: Revenue Forecasts (U.S.), 1998-2008

Decision Support Database
  • Incidence of Myocardial Infarction (World - 38 Countries across 7 regions), 1996-2004
  • Mortality due to Myocardial Infarction (World - 37 Countries across 7 regions), 1996-2004
  • Mortality due to Coronary Heart Disease (World - 41 Countries across 7 regions), 1996-2004
  • Prevalence percent of Cardiovascular Diseases (World - 44 Countries across 7 regions), 1996-2004
  • Prevalence of Obese Population (World - 39 Countries across 7 regions), 1996-2004
  • Diabetes Prevalence (World - 45 Countries across 7 regions), 1996-2004
  • Prevalence of Hypertension (World - 42 Countries across 7 regions), 1996-2004
  • Male Population over 65 Years of Age (World - 46 Countries including Other Countries' category for 6 regions), 1996-2004
  • Female Population over 65 Years of Age (World - 46 Countries including Other Countries' category for 6 regions), 1996-2004
  • Total Population over 65 Years of Age (World - 46 Countries including Other Countries' category for 6 regions), 1996-2004

  More Information
Please print out this form, complete your details and fax it to Frost & Sullivan:
Latin & North America:
Frost & Sullivan
Sales Department
7550 West Interstate 10
Suite 400
San Antonio
Texas 78229-5616. USA
Fax: 888.690.3329
Asia Pacific:
Frost & Sullivan
Sales Department
100 Beach Road
#29-01/11, Shaw Tower
Singapore 189702
SINGAPORE
Fax: +65 68900988
EMEA:
Frost & Sullivan
Sales Department
Sullivan House
4 Grosvenor Gardens
London SW1W 0DH. UK
Fax: +44(0) 1865 389 515
SERVICE INQUIRY


I would like information on:
U.S. Lipid Regulators Markets (A181-01-00-00-00)

YOUR DETAILS

Name Address
Title
Company
Telephone State/Province
Fax Zip/Postal Code
Email Country
Select the markets that interest you Tell us the services that interest you
Aerospace & Defense
Automotive & Transportation
Business & Financial Services
Career Research
Chemicals, Materials & Foods
Consumer Products
Education
Electronics and Security
Energy & Power Systems
Environment & Building Technologies
Healthcare
Industrial Automation
Information & Communication Tech.
Measurement & Instrumentation
Metals & Minerals
 
Growth Partnership Services
Growth Team Membership
Growth Strategy Dialogue
Growth Consulting
Growth Workshops
Events
Corporate Training & Development
Best Practices Research
Technical Research
Econometric Research
Market Engineering Research
Customer Research
Financial Benchmarking & Analysis
Stratecast: Telecoms Strategic Forecasting
Career Opportunities
Press Support Services
Comments: (For instance 'Please send me more information on...')

  Further Information

Enquiries from:
Africa:
Tel:+27 21 680 3260
Email: enquiries@frost.com

Enquiries from:
Asia Pacific:
Tel: +65 68900999
Email: apacfrost@frost.com
 
Enquiries from:
Europe:
Tel: +44 (0) 20 7343 8383
Email: enquiries@frost.com
Enquiries from:
Latin America:
Tel: +54 11 4777 1550
Email: myfrost.la@frost.com
 

Enquiries from:
Middle East and North Africa:
Tel: +971.4.4331.893
Email: meenquiries@frost.com

Enquiries from:
North America:
Tel:+1.877.GO.FROST (463.7678)
Email: enquiries@frost.com
 

Enquiries from:
South Asia:
Tel: +91 (0) 22 6160 6666
Email: safrost@frost.com




 
For a full list of our offices click here.
 
Conseq